7733 Stock Overview
Olympus Corporation manufactures and sells precision machineries and instruments worldwide.
No risks detected for 7733 from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||JP¥2,686.50|
|52 Week High||JP¥2,834.50|
|52 Week Low||JP¥1,998.00|
|1 Month Change||-0.26%|
|3 Month Change||15.77%|
|1 Year Change||24.78%|
|3 Year Change||122.03%|
|5 Year Change||163.38%|
|Change since IPO||701.94%|
Recent News & Updates
|7733||JP Medical Equipment||JP Market|
Return vs Industry: 7733 exceeded the JP Medical Equipment industry which returned -14.6% over the past year.
Return vs Market: 7733 exceeded the JP Market which returned -7% over the past year.
|7733 Average Weekly Movement||5.6%|
|Medical Equipment Industry Average Movement||4.6%|
|Market Average Movement||4.2%|
|10% most volatile stocks in JP Market||8.4%|
|10% least volatile stocks in JP Market||2.2%|
Stable Share Price: 7733 is not significantly more volatile than the rest of JP stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 7733's weekly volatility (6%) has been stable over the past year.
About the Company
Olympus Corporation manufactures and sells precision machineries and instruments worldwide. It operates through four segments: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, and Others. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopes, endoscopy system, and repair services.
Olympus Fundamentals Summary
|7733 fundamental statistics|
Is 7733 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|7733 income statement (TTM)|
|Cost of Revenue||JP¥297.17b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 09, 2022
|Earnings per share (EPS)||90.92|
|Net Profit Margin||13.32%|
How did 7733 perform over the long term?See historical performance and comparison
0.6%Current Dividend Yield
Is 7733 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 7733?
Other financial metrics that can be useful for relative valuation.
|What is 7733's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 7733's PE Ratio compare to its peers?
|7733 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
6849 Nihon Kohden
Price-To-Earnings vs Peers: 7733 is expensive based on its Price-To-Earnings Ratio (29.5x) compared to the peer average (26x).
Price to Earnings Ratio vs Industry
How does 7733's PE Ratio compare vs other companies in the JP Medical Equipment Industry?
Price-To-Earnings vs Industry: 7733 is expensive based on its Price-To-Earnings Ratio (29.5x) compared to the JP Medical Equipment industry average (14.4x)
Price to Earnings Ratio vs Fair Ratio
What is 7733's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||29.5x|
|Fair PE Ratio||33x|
Price-To-Earnings vs Fair Ratio: 7733 is good value based on its Price-To-Earnings Ratio (29.5x) compared to the estimated Fair Price-To-Earnings Ratio (33x).
Share Price vs Fair Value
What is the Fair Price of 7733 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 7733 (¥2686.5) is trading below our estimate of fair value (¥3309.35)
Significantly Below Fair Value: 7733 is trading below fair value, but not by a significant amount.
Price to Earnings Growth Ratio
PEG Ratio: 7733 is poor value based on its PEG Ratio (2.6x)
Discover undervalued companies
How is Olympus forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 7733's forecast earnings growth (11.4% per year) is above the savings rate (0.04%).
Earnings vs Market: 7733's earnings (11.4% per year) are forecast to grow faster than the JP market (8.9% per year).
High Growth Earnings: 7733's earnings are forecast to grow, but not significantly.
Revenue vs Market: 7733's revenue (6.7% per year) is forecast to grow faster than the JP market (4.5% per year).
High Growth Revenue: 7733's revenue (6.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 7733's Return on Equity is forecast to be high in 3 years time (22%)
Discover growth companies
How has Olympus performed over the past 5 years?
Past Performance Score6/6
Past Performance Score 6/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 7733 has high quality earnings.
Growing Profit Margin: 7733's current net profit margins (13.3%) are higher than last year (9%).
Past Earnings Growth Analysis
Earnings Trend: 7733's earnings have grown by 9.4% per year over the past 5 years.
Accelerating Growth: 7733's earnings growth over the past year (76.4%) exceeds its 5-year average (9.4% per year).
Earnings vs Industry: 7733 earnings growth over the past year (76.4%) exceeded the Medical Equipment industry 14.9%.
Return on Equity
High ROE: 7733's Return on Equity (22.7%) is considered high.
Discover strong past performing companies
How is Olympus's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 7733's short term assets (¥694.6B) exceed its short term liabilities (¥376.3B).
Long Term Liabilities: 7733's short term assets (¥694.6B) exceed its long term liabilities (¥470.4B).
Debt to Equity History and Analysis
Debt Level: 7733's net debt to equity ratio (14.3%) is considered satisfactory.
Reducing Debt: 7733's debt to equity ratio has increased from 66.5% to 75.5% over the past 5 years.
Debt Coverage: 7733's debt is well covered by operating cash flow (44%).
Interest Coverage: 7733's interest payments on its debt are well covered by EBIT (45.8x coverage).
Discover healthy companies
What is Olympus's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 7733's dividend (0.6%) isn’t notable compared to the bottom 25% of dividend payers in the JP market (1.69%).
High Dividend: 7733's dividend (0.6%) is low compared to the top 25% of dividend payers in the JP market (3.74%).
Stability and Growth of Payments
Stable Dividend: 7733 is not paying a notable dividend for the JP market, therefore no need to check if payments are stable.
Growing Dividend: 7733 is not paying a notable dividend for the JP market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: 7733 is not paying a notable dividend for the JP market.
Cash Payout to Shareholders
Cash Flow Coverage: 7733 is not paying a notable dividend for the JP market.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Yasuo Takeuchi (65 yo)
Mr. Yasuo Takeuchi has been Chief Executive Officer and President of Olympus Corporation since April 1, 2019 and has been its Representative Executive Officer since 2019. He served as Chief Financial Offic...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Yasuo's total compensation is reasonable compared to companies of similar size in the JP market.
Compensation vs Earnings: Insufficient data to compare Yasuo's compensation with company performance.
Experienced Management: 7733's management team is considered experienced (2.3 years average tenure).
Experienced Board: 7733's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Olympus Corporation's employee growth, exchange listings and data sources
- Name: Olympus Corporation
- Ticker: 7733
- Exchange: TSE
- Founded: 1919
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: JP¥3.420t
- Shares outstanding: 1.27b
- Website: https://www.olympus-global.com
Number of Employees
- Olympus Corporation
- Shinjuku Monolith
- 3-1 Nishi-Shinjuku 2-chome
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/02 00:00|
|End of Day Share Price||2022/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.